Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Dose-Escalation Study of HTX-034 Following Bunionectomy

NCT: NCT04398329 · COMPLETED

NCT IDNCT04398329
StatusCOMPLETED
Start Date2020-05-08
Completion2021-07-15
SponsorHeron Therapeutics (INDUSTRY)
First posted
Last updated

Brief Summary

This was a Phase 1b/2, randomized, blinded, active-controlled study. Phase 1b evaluated escalating doses of HTX-034 compared with bupivacaine HCl. Phase 2 was a dose-expansion phase to evaluate additional subjects treated with the HTX-034 dose selected based on Phase 1b, compared with bupivacaine HCl.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑